

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3942906

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
MILLENNIUM PHARMACEUTICALS, INC.	03/19/2015
RECEIVING PARTY DATA	
Name:	IMMUNOGEN, INC.
Street Address:	830 WINTER STREET
City:	WALTHAM
State/Country:	MASSACHUSETTS
Postal Code:	02451
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	7598375
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6174496500
Email:	DOCKET@MCCARTER.COM
Correspondent Name:	MCCARTER & ENGLISH, LLP
Address Line 1:	265 FRANKLIN STREET
Address Line 4:	BOSTON, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	121162-00001
NAME OF SUBMITTER:	STEVEN G. DAVIS
SIGNATURE:	/Steven G. Davis/
DATE SIGNED:	06/30/2016
Total Attachments: 5	
source=Recordation_Document_FINAL#page1.tif	
source=Recordation_Document_FINAL#page2.tif	
source=Recordation_Document_FINAL#page3.tif	
source=Recordation_Document_FINAL#page4.tif	
source=Recordation_Document_FINAL#page5.tif	

MULTI-TARGET AGREEMENT

This Multi-Target Agreement (this “Agreement”) is made effective as of the date of the last signature below (the “Effective Date”) by and between **ImmunoGen, Inc.**, a Massachusetts corporation (“ImmunoGen”), with its principal place of business at 830 Winter Street, Waltham, Massachusetts 02451, and **Millennium Pharmaceuticals, Inc.**, a Delaware corporation (“Millennium”) and a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, with its principal place of business at 40 Landsdowne Street, Cambridge, Massachusetts 02139. ImmunoGen and Millennium are sometimes each hereinafter referred to individually as a “Party” and collectively as the “Parties.”

WHEREAS, Millennium is the owner of or otherwise controls certain rights in Technology relating to certain Antibodies directed to specified Targets and the conjugation of Antibodies with payloads; and

WHEREAS, ImmunoGen is the owner of or otherwise controls certain rights in Technology relating to or otherwise useful in the conjugation of Cytotoxic Compounds to Antibodies; and

WHEREAS, pursuant to the terms and conditions set forth herein, Millennium desires to have access to ImmunoGen’s Technology (and associated Patent Rights) for research, discovery and development of ADCs to specified Targets, and ImmunoGen desires to give Millennium such access.

NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties hereby agree as follows:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

7.7 Assignment of Millennium Process Patents. [REDACTED]

[REDACTED] Millennium agrees to assign, and hereby does assign, and further agrees to cause its Affiliates to assign, all of its and their right, title and interest in and to the Patent Rights listed in **Schedule B** attached hereto and incorporated herein by reference (the “**Millennium Process Patents**”), and in connection therewith, Millennium shall take, and shall cause its Affiliates to take, all actions and execute all documents reasonably necessary to assign ownership of the Millennium Process Patents to ImmunoGen.

[REDACTED]

[REDACTED]

SCHEDULE B

MILLENNIUM PROCESS PATENTS

Method of Acylating Maytansinoid with Chiral Amino Acids

Australia: Patent No. 2006280146

Canada: Patent No. 2617953

Europe: Patent No. 1913002 (France; Germany; and Great Britain)

Japan: Patent No. 5167130

U.S.A: Patent No. 7,598,375

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives.

IMMUNOGEN, INC.

MILLENNIUM PHARMACEUTICALS,
INC.

By: Peter A. Williams

By: _____

Name: PETER WILLIAMS

Name: _____

Title: VICE PRESIDENT

Title: _____

Date: March 20, 2015

Date: _____

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives.

IMMUNOGEN, INC.

MILLENNIUM PHARMACEUTICALS,
INC.

By: _____

Name: _____

Title: _____

Date: _____

By: C. Jim _____

Name: Ch. Jimachi _____

Title: President _____

Date: March 19, 2015 _____